Read more
Informationen zum Autor Pamela Greenwell is Principal Lecturer at The University of Westminster. She leads a research team in glycobiology, molecular biology and bioinformatics and is actively involved with enabling research in clinical trials between academics, industry and Primary Care Trusts. Michelle McCulley has a background in human genetics and experience teaching a broad range of students and health professionals, she is currently a Senior Teaching fellow at the Peninsula Medical School. Klappentext Molecular therapeutics incorporates genetics, recombinant DNA technology, biochemistry, protein production and purification, microbiology, molecular biology, immunology, pathobiology, and biotechnology. It addresses the treatment of human beings with "new drugs" and poses a range of ethical issues, particularly with respect to clinical trials, animal models, financial considerations and availability of treatment.Recent advances in molecular therapeutics means that many of these cutting edge methods will soon be ready to be considered for clinical trial. It is essential that scientists, doctors, nurses and allied health professionals involved in these novel therapies understand how these techniques have evolved, what their benefits and drawbacks might be, the ethical issues associated with them and what their potential is for the future.Targeted at postgraduate and undergraduate biomedical, allied health, medical and life science students, 'Molecular Therapeutics' provides an invaluable introduction to this rapidly evolving field. Zusammenfassung By taking advantage of recent advances and increased understanding in the field of human genetics, Molecular Therapeutics: 21st Century Medicine provides essential background knowledge and key literature on a broad range of novel approaches and disciplines. Inhaltsverzeichnis Prologue. 1 Introduction. 1.1 Microbial diseases. 1.2 Cancer and heart disease. 1.3 Genetic diseases. 1.4 Role of molecular biology in therapeutics. 2 Prenatal diagnosis and pre-implementation. 2.1 Should we treat inherited diseases? 2.2 Genetic screening. 2.2.1 Pre-implementation genetic diagnosis. 2.3 Counselling. 3 Simple protein replacement therapy. 3.1 Preventing transfusion-transmissible infectious diseases in the UK. 3.2 Ensuring the safety of organ transplants. 3.3 Preventing transfusion-transmissible infectious diseases worldwide. 3.4 HIV. 4 Recombinant protein production. 4.1 Choice of organism. 4.2 Alternatives to E. coli for the production of recombinant proteins. 4.3 Problems with recombinant protein production. 4.4 All recombinants must be tested before they are given to humans. 4.5 Why make recombinant proteins? 4.6 Recombinant products. 4.7 Generics. 5 Recombinant vaccines. 5.1 Vaccine history. 5.2 Vaccines. 5.3 Vaccine methods. 5.4 Types of vaccine. 5.5 The limitations of vaccine programmes. 5.6 The role of the WHO. 5.7 Problems specific to developing countries. 5.8 Economics and logistics of vaccinology. 5.9 Recombinant vaccines. 5.10 Rational design: bioinformatics and proteomics. 5.11 Other interesting areas for vaccine development. 5.12 Conclusion. 6 Therapeutic antibodies and immunotherapy. 6.1 Monoclonal antibodies. 6.2 Monoclonal production. 6.3 Therapeutic monoclonal antibodies. 6.4 Transgenic monoclonals. 6.5 The uses of monoclonal antibodies in therapy. 6.6 Specific examples of therapeutic strategies. 6.7 Other recombinant proteins used in immunotherapy. 7 Transgenic animals. 7.1 Why do we want to engineer the genomes of animals? 7.2 Experimental procedure. 7.3 DNA constructs, insertiona...
